{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T05:21:23Z","timestamp":1704345683932},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T00:00:00Z","timestamp":1456358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00415-015-7999-6","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T04:29:13Z","timestamp":1456374553000},"page":"606-610","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Acute relapse after initiation of Siponimod in a patient with secondary progressive MS"],"prefix":"10.1007","volume":"263","author":[{"given":"Rehana","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fides M.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tresa E.","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Litvak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sguigna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Marder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karanjit","family":"Kooner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"issue":"2","key":"7999_CR1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1073\/pnas.1014154108","volume":"108","author":"JW Choi","year":"2011","unstructured":"Choi JW, Gardell SE, Herr DR et al (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 108(2):751\u2013756","journal-title":"Proc Natl Acad Sci USA"},{"key":"7999_CR2","unstructured":"Exploring the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (EXPAND) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01665144"},{"issue":"4","key":"7999_CR3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","volume":"366","author":"D Pelletier","year":"2012","unstructured":"Pelletier D, Hafler DA (2012) Fingolimod for multiple sclerosis. New Engl J Med 366(4):339\u2013347","journal-title":"New Engl J Med"},{"issue":"1","key":"7999_CR4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","volume":"115","author":"V Brinkmann","year":"2007","unstructured":"Brinkmann V (2007) Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115(1):84\u2013105","journal-title":"Pharmacol Ther"},{"issue":"11","key":"7999_CR5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T et al (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9(11):883\u2013897","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"7999_CR6","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.0b013e31820d9507","volume":"76","author":"B Soliven","year":"2011","unstructured":"Soliven B, Miron V, Chun J (2011) The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology 76(8):S9\u201314","journal-title":"Neurology"},{"issue":"3","key":"7999_CR7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278\u2013286","journal-title":"Neurology"},{"issue":"8","key":"7999_CR8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","volume":"12","author":"K Selmaj","year":"2013","unstructured":"Selmaj K, Li DK, Hartung HP et al (2013) Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12(8):756\u2013767","journal-title":"Lancet Neurol"},{"issue":"14","key":"7999_CR9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","volume":"76","author":"MC Kowarik","year":"2011","unstructured":"Kowarik MC, Pellkofer HL, Cepok S et al (2011) Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 76(14):1214\u20131221","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7999-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-015-7999-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7999-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:22:58Z","timestamp":1559056978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-015-7999-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,25]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["7999"],"URL":"https:\/\/doi.org\/10.1007\/s00415-015-7999-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,25]]}}}